Compare · ATRA vs MRKR
ATRA vs MRKR
Side-by-side comparison of Atara Biotherapeutics Inc. (ATRA) and Marker Therapeutics Inc. (MRKR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ATRA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while MRKR focuses on Biotechnology: Pharmaceutical Preparations.
- ATRA is the larger of the two at $64.5M, about 3.5x MRKR ($18.2M).
- ATRA has been more active in the news (5 items in the past 4 weeks vs 3 for MRKR).
- ATRA has more recent analyst coverage (10 ratings vs 2 for MRKR).
- Company
- Atara Biotherapeutics Inc.
- Marker Therapeutics Inc.
- Price
- -
- -
- Market cap
- $64.5M
- $18.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 5
- 3
- Recent ratings
- 10
- 2
Atara Biotherapeutics Inc.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Marker Therapeutics Inc.
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Latest ATRA
- President and CEO Anhco Nguyen sold $39,368 worth of shares (6,094 units at $6.46), decreasing direct ownership by 5% to 126,681 units (SEC Form 4) (tax liability)
- SEC Form S-3 filed by Atara Biotherapeutics Inc.
- SEC Form 10-Q filed by Atara Biotherapeutics Inc.
- Atara Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
- Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
- Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
- Director Cherry Brian N bought $999,994 worth of shares (104,166 units at $9.60), increasing direct ownership by 167% to 166,486 units (SEC Form 4)
- President and CEO Nguyen Anhco sold $40,883 worth of shares (5,062 units at $8.08), decreasing direct ownership by 4% to 132,775 units (SEC Form 4) (withholding obligation)
- SEC Form 10-Q filed by Atara Biotherapeutics Inc.
Latest MRKR
- Marker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
- SEC Form 10-Q filed by Marker Therapeutics Inc.
- Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
- SEC Form 8-K filed by Marker Therapeutics Inc.
- Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
- SEC Form 10-Q filed by Marker Therapeutics Inc.
- SEC Form 10-Q filed by Marker Therapeutics Inc.
- Marker Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Marker Therapeutics Inc.